Similarly, the expansion of what physicians consider HER2+ for therapeutic purposes (HER2-low and HER2-ultra-low tumors) [4] has led to therapeutic overlap, wherein patients with similar breast cancer subsets may receive both agents. Here, ERBB2 is linked to breast carcinoma.